Opinion|Videos|June 5, 2024
Clinical Impact of the Introduction of Disease-Modifying Treatments for Alzheimer Disease
Experts on Alzheimer disease discuss how the introduction of disease-modifying therapies has impacted the treatment landscape.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- What has been the clinical impact and the target patients for the use of anti-amyloid β monoclonal antibodies?
- Aducanumab approved by the FDA in 2021; development and commercialization discontinued on Jan 31, 2024
- Lecanemab approved by the FDA in 2023
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Congress Unveils Massive Funding Bill to Avert Shutdown
2
ctDNA Positivity Associated With Worse Survival, Higher Recurrence Risk in Patients With NSCLC
3
Novel CLL Therapies Prompt New Treatment Considerations
4
Early Data Show Feasibility of in Vivo CAR T Therapy in Multiple Myeloma
5
